Literature DB >> 22556353

Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82.

Michael Lauseker, Markus Pfirrmann, Verena S Hoffmann, Joerg Hasford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22556353      PMCID： PMC3342986          DOI： 10.3324/haematol.2011.061630

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.

Authors:  F Guilhot; C Chastang; M Michallet; A Guerci; J L Harousseau; F Maloisel; R Bouabdallah; D Guyotat; N Cheron; F Nicolini; J F Abgrall; J Tanzer
Journal:  N Engl J Med       Date:  1997-07-24       Impact factor: 91.245

2.  Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.

Authors:  Amr R Ibrahim; Richard E Clark; Tessa L Holyoake; Jenny Byrne; Pat Shepherd; Jane F Apperley; Dragana Milojkovic; Richard Szydlo; John Goldman; David Marin
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

Review 3.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Michele Baccarani; Giuseppe Saglio; John Goldman; Andreas Hochhaus; Bengt Simonsson; Frederick Appelbaum; Jane Apperley; Francisco Cervantes; Jorge Cortes; Michael Deininger; Alois Gratwohl; François Guilhot; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Dietger Niederwieser; Richard Silver; Rudiger Hehlmann
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

4.  Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Authors:  Susanne Saussele; Michael Lauseker; Alois Gratwohl; Dietrich W Beelen; Donald Bunjes; Rainer Schwerdtfeger; Hans-Jochem Kolb; Anthony D Ho; Christiane Falge; Ernst Holler; Günter Schlimok; Axel R Zander; Renate Arnold; Lothar Kanz; Robert Dengler; Claudia Haferlach; Brigitte Schlegelberger; Markus Pfirrmann; Martin C Müller; Susanne Schnittger; Armin Leitner; Nadine Pletsch; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

5.  Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

Authors:  R Hehlmann; H Heimpel; J Hasford; H J Kolb; H Pralle; D K Hossfeld; W Queisser; H Löffler; A Hochhaus; B Heinze
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

6.  Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.

Authors:  R Hehlmann; U Berger; M Pfirrmann; A Hochhaus; G Metzgeroth; O Maywald; J Hasford; A Reiter; D K Hossfeld; H-J Kolb; H Löffler; H Pralle; W Queisser; M Griesshammer; C Nerl; R Kuse; A Tobler; H Eimermacher; A Tichelli; C Aul; M Wilhelm; J T Fischer; M Perker; C Scheid; M Schenk; J Weiss; C R Meier; S Kremers; L Labedzki; T Schmeiser; H-P Lohrmann; H Heimpel
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

7.  Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.

Authors:  David Marin; Sarah Marktel; Richard Szydlo; John P Klein; Marco Bua; Nicola Foot; Eduardo Olavarria; Pat Shepherd; Edward Kanfer; John M Goldman; Jane F Apperley
Journal:  Lancet       Date:  2003-08-23       Impact factor: 79.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.